Adagene Announces Investigator Initiated Phase 2 Trial For Neoadjuvant Muzastotug In Colorectal Cancer
Benzinga Newsdesk 1 year ago
BiotechNewsGeneral
- Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoint of rate of major pathological response -SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc.
- Trial to begin enrolling in April; expected primary completion in mid-2027 -
- Primary study endpoint of rate of major pathological response -
SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced an investigator initiated (IIT) Phase 2 neoadjuvant trial of ADG126 for patients with stage II or stage III colorectal cancer.